PuraPharm (HKSE:01498) Net Income From Continuing Operations : HK$-29.1 Mil (TTM As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is PuraPharm Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. PuraPharm's net income from continuing operations for the six months ended in Dec. 2024 was HK$-14.4 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-29.1 Mil.

PuraPharm Net Income From Continuing Operations Historical Data

The historical data trend for PuraPharm's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PuraPharm Net Income From Continuing Operations Chart

PuraPharm Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Income From Continuing Operations

Get a 7-Day Free Trial

40.22

-117.19

-119.18

-102.31

-29.14

PuraPharm Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Net Income From Continuing Operations	Get a 7-Day Free Trial															-84.48	-36.51	-65.80	-14.77	-14.38

PuraPharm Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-29.1 Mil.

PuraPharm Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PuraPharm Corporation Ltd (HKSE:01498) » Definitions » Net Income From Continuing Operations

Traded in Other Exchanges

N/A

Address

Wireless Centre, Phase One, Unit 201-207, 2nd Floor, Hong Kong Science Park, Tai Po, New Territories, Hong Kong, HKG

Website

https://www.purapharm.com

PuraPharm Corporation Ltd is a Hong Kong-based Chinese medicine Company. It is engaged in the research and development, production, marketing, and sale of concentrated Chinese medicine granules (CCMG) products marketed under the brand Nong's. The organization provides Chinese medical diagnostic services and operates through several segments: China CCMG, Hong Kong CCMG, Chinese healthcare products, Plantation, and Clinics. The majority of its revenue comes from the Hong Kong CCMG segment, which mainly involves the sale of CCMG products, excluding sales through self-operated clinics in Hong Kong. The group derives revenue from customers located in Hong Kong, Mainland China, and Other countries.

Executives

Chan Yu Ling, Abraham	2101 Beneficial owner
Man Yee Wai, Viola	2202 Interest of your spouse
Fullgold Development Limited	2101 Beneficial owner

PuraPharm Headlines

No Headlines